Novo Nordisk A/S purchases B shares worth DKK 4,109 million from Novo Holdings A/S under the 2021 share repurchase programme
November 05 2021 - 4:50PM
Novo Nordisk A/S purchases B shares worth DKK 4,109 million from
Novo Holdings A/S under the 2021 share repurchase programme
Bagsværd, Denmark, 5
November 2021 — Novo
Nordisk A/S has today entered into an agreement to purchase
5,610,000 B shares of DKK 0.20 to a value of DKK 4,109 million from
Novo Holdings A/S. This transaction is part of Novo Nordisk A/S’
2021 share repurchase programme of up to a total of DKK 20 billion
to be executed during a 12-month period beginning 3 February 2021.
The transaction price is DKK 732.48 per share and has been
calculated as the three-day volume weighted average market price
from 3 November 2021 to 5 November 2021 in the open window
following the announcement of Novo Nordisk A/S’ quarterly financial
results.
Prior to the sale of B shares, Novo Holdings A/S’ ownership of
Novo Nordisk A/S was 28.3% of the share capital and 76.8% of the
votes. Following the transaction, Novo Holdings A/S owns
537,436,000 A shares of DKK 0.20 and 110,519,000 B shares of DKK
0.20, corresponding to 28.1% of the capital and 76.7% of the votes
in Novo Nordisk A/S.
The transaction is in line with the announcement on 3 November
2021 that Novo Holdings A/S intends to maintain its ownership of
Novo Nordisk A/S’ share capital around 28%.
In addition, transactions related to Novo Nordisk’s incentive
programmes have resulted in a net transfer from Novo Nordisk of
50,721 B shares in the period from 3 November 2021 to 5 November
2021.
With the transactions stated above, Novo Nordisk A/S owns a
total of 28,192,626 B shares of DKK 0.20, corresponding to 1.2% of
the share capital, as treasury shares. The total amount of A and B
shares in the company is 2,310,000,000 of DKK 0.20 including
treasury shares.
About Novo Holdings A/S
Novo Holdings A/S
is a private limited liability company wholly owned by the Novo
Nordisk Foundation. It is the holding company of the Novo Group,
comprising Novo Nordisk A/S and Novozymes A/S, and is responsible
for managing the Novo Nordisk Foundation’s assets. Novo Holdings is
recognized as a leading international life science investor, with a
focus on creating long-term value. As a life science investor, Novo
Holdings provides seed and venture capital to development-stage
companies and takes significant ownership positions in growth and
well-established companies. Novo Holdings also manages a broad
portfolio of diversified financial assets. Further information:
www.novoholdings.dk.
About Novo Nordisk A/SNovo Nordisk is a leading
global healthcare company, founded in 1923 and headquartered in
Denmark. Our purpose is to drive change to defeat diabetes and
other serious chronic diseases such as obesity and rare blood and
endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to
prevent and ultimately cure disease. Novo Nordisk employs about
47,000 people in 80 countries and markets its products in around
170 countries. Novo Nordisk's B shares are listed on Nasdaq
Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com,
Facebook, Twitter, LinkedIn, and YouTube.
Further information
Media: |
|
|
Mette Kruse
Danielsen |
+45 3079 3883 |
mkd@novonordisk.com |
Michael Bachner
(US) |
+1 609 664
7308 |
mzyb@novonordisk.com |
|
|
|
Investors: |
|
|
Daniel Muusmann
Bohsen |
+45 3075 2175 |
dabo@novonordisk.com |
Ann Søndermølle
Rendbæk |
+45 3075 2253 |
arnd@novonordisk.com |
David Heiberg
Landsted |
+45 3077 6915 |
dhel@novonordisk.com |
Mark Joseph Root
(US) |
+1 848 213
3219 |
mjhr@novonordisk.com |
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (TG:NOVC)
Historical Stock Chart
From Jul 2023 to Jul 2024